Exelixis (NasdaqGS:EXEL) reported that the FDA has accepted its New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The filing is based on phase 3 STELLAR-303 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results